Stephen Hodi, MD
Director, Melanoma Center and Center for Immuno-Oncology, Dana-Farber/Brigham and Women’s Cancer Center
Professor of Medicine and Sharon Crowley Martin Chair in Melanoma, Harvard Medical School
Dr. Hodi received his MD degree from Cornell University Medical College in 1992, completed postdoctoral training in internal medicine at the Hospital of the University of Pennsylvania and medical oncology training at Dana-Farber Cancer Institute, where he joined the faculty in 1995. His research focuses on gene therapy, the development of immune therapies, and first-in-human studies for malignant melanoma.
Dr. Hodi is an internationally recognized leader in developing checkpoint inhibitors. He led the first human trial of ipilimumab, which blocks the CTLA-4 checkpoint, and later led the phase III registration trial that led to FDA approval of ipilimumab in melanoma. Dr. Hodi has continued as a principal investigator in the clinical development of a second family of checkpoint inhibitors, which block PD-1 and PD-L1, and other novel combination therapies. Dr. Hodi is a member of the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma Committee, the International Society for the Biological Therapy of Cancer, and a founding member of the Society for Melanoma Research.